Sanofi and Glaxo are restarting trial
Sanofi and GlaxoSmithKline PLC are restarting a trial of their coronavirus vaccine, a step forward for a shot that got delayed by a problematic study in the fall.
As two of the world's biggest vaccine-makers, Sanofi and Glaxo have faced heavy criticism for failing to lead the way on inoculating against the coronavirus — putting them in stark contrast to the likes of biotechs BioNTech SE and Moderna Inc., which developed highly effective shots in less than a year.
Separately, Sanofi said it has agreed to make a plant in France available to Johnson & Johnson for the formulation and filling of about 12 million doses a month of that company’s COVID-19 shot. J&J’s vaccine is being reviewed for emergency clearance in the U.S.